# Intravenous Immunoglobulins for Prevention of BKV Infection in Kidney Transplant Recipients According to BKV Genotype-specific Neutralizing Antibody Titers at the Day of Transplantation.

> **NCT04222023** · PHASE4 · COMPLETED · sponsor: **University Hospital, Strasbourg, France** · enrollment: 359 (actual)

## Conditions studied

- Kidney Transplantation

## Interventions

- **DRUG:** Intravenous immunoglobulins (IVIG)

## Key facts

- **NCT ID:** NCT04222023
- **Lead sponsor:** University Hospital, Strasbourg, France
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-21
- **Primary completion:** 2025-08-01
- **Final completion:** 2025-08-01
- **Target enrollment:** 359 (ACTUAL)
- **Last updated:** 2025-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04222023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04222023, "Intravenous Immunoglobulins for Prevention of BKV Infection in Kidney Transplant Recipients According to BKV Genotype-specific Neutralizing Antibody Titers at the Day of Transplantation.". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT04222023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*